WEBPress releases. September 16 2024 Brooke Shields Partners with GSK to Educate Adults 50 and Older About Their Shingles Risk. September 11 2024 Statement: Zantac (ranitidine) litigation – Dixon case. September 06 2024 GSK announces positive results from phase III trial of Nucala (mepolizumab) in COPD. View all press releases.
WEBWe are a focused biopharma company with strong momentum and big ambitions, to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.
WEBGSK is the tenth largest pharmaceutical company and #294 on the 2022 Fortune Global 500, ranked behind other pharmaceutical companies China Resources, Sinopharm, Johnson & Johnson, Pfizer, Roche, AbbVie, Novartis, Bayer, and Merck Sharp & Dohme.
WEBProducts. Learn more about our product portfolio and how we're prioritizing vaccines and specialty medicines to get ahead of disease together. Below you can find the full A-Z list of our products available in the United States.
WEBAt a glance. GSK has a significant footprint in the US across commercial, R&D, manufacturing, and corporate functions. We employ ~15,000 people across the US and have two corporate hubs. Explore GSK in the US.
WEBSpecialty medicines are prescribed by specialist healthcare practitioners. Our portfolio of specialty medicines prevents and treats diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Many are first or best-in-class.
WEBGlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. [4][5] The company's product portfolio includes prescription medicines and vaccines.
WEBGSK plc, based in Brentford, UK, is a global healthcare company engaged in the discovery, development, manufacture and marketing of pharmaceutical products. The company's leading products...
WEBJun 1, 2021 · The Sanofi/GSK vaccine candidate is a recombinant protein-based vaccine based on the baculovirus, which is commonly found in moths. Pieces of the novel coronavirus are used in combination with the baculovirus to effectively program the immune system to better recognize and fight COVID-19.